Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.36 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.36 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.35 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.34 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16644423 | 1.00 | POLB (0.40) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL20611194 | 0.90 | POLB (0.40) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL22475111 | 0.89 | POLB (0.39) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL9893412 | 0.88 | POLB (0.40) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL9893411 | 0.88 | POLB (0.40) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL19993734 | 0.87 | POLB (0.39) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL15074335 | 0.87 | POLB (0.39) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL18672099 | 0.86 | POLB (0.39) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL18672098 | 0.86 | POLB (0.39) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL15074434 | 0.86 | POLB (0.39) | POLBMEN1USP2KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044369-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2018-02-15 | — | — | US | disclosed |
| US-9187515-B2 | 2′,4′-fluoro nucleosides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| WO-2015054465-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2014165542-A1 | 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140294769-A1 | 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS LLC | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044369-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NUDT1 | POLB 346/4885MEN1 3891/4885USP2 4791/4885 |
| US-20140294769-A1 | 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | SLC29A1, SLC28A1, SLC10A1 | POLB 322/4885MEN1 4739/4885USP2 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.